BioNTech: Founders Announce Withdrawal and Stock Plummets 18% in Pre-Market!
Reading Time: 2 minutes
BioNTech SE (NASDAQ: BNTX) reported revenues of €2.9 billion for the fiscal year 2025, slightly more than in the previous year. At the same time, the company recorded a net loss of €1.1 billion, primarily due to high investments in research & development as well as extraordinary costs. In the fourth quarter, revenues were about €907 million, significantly below the previous year's figure. The main reason for the decline is the decreasing demand for COVID-19 vaccines. Nevertheless, the company's financial foundation remains very solid:...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
